Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

Quick Facts

  • 350 women recruited into a prospective study
  • Approximately of women reported using medications for UF-associated pain
  • Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

Challenge

  • Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
  • Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
  • Myovant had two main objectives:
  • Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
  • Assess the real-world utilization of therapies to treat these symptoms of UF

Approach

  • Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
  • In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

Results

  • Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
  • These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
  • Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF

Have questions?

CONTACT US
Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

Quick Facts

  • 350 women recruited into a prospective study
  • Approximately of women reported using medications for UF-associated pain
  • Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

Challenge

  • Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
  • Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
  • Myovant had two main objectives:
  • Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
  • Assess the real-world utilization of therapies to treat these symptoms of UF

Approach

  • Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
  • In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

Results

  • Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
  • These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
  • Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF

Have questions?

CONTACT US
Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

Quick Facts

  • 350 women recruited into a prospective study
  • Approximately of women reported using medications for UF-associated pain
  • Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

Challenge

  • Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
  • Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
  • Myovant had two main objectives:
  • Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
  • Assess the real-world utilization of therapies to treat these symptoms of UF

Approach

  • Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
  • In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

Results

  • Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
  • These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
  • Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF

Have questions?

CONTACT US
Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

Quick Facts

  • 350 women recruited into a prospective study
  • Approximately of women reported using medications for UF-associated pain
  • Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

Challenge

  • Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
  • Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
  • Myovant had two main objectives:
  • Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
  • Assess the real-world utilization of therapies to treat these symptoms of UF

Approach

  • Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
  • In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

Results

  • Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
  • These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
  • Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF

Have questions?

CONTACT US

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

June 13, 2023
Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

June 13, 2023
Case Studies

June 13, 2023
Case Studies

The patient-perceived burden of pain in uterine fibroids: Results from a prospective real-world evidence study

June 13, 2023
Case Studies
Eve: Evidation's brand mark which is a yellow glowing orb

Quick Facts

  • 350 women recruited into a prospective study
  • Approximately of women reported using medications for UF-associated pain
  • Participants experienced, on average, a 9-year gap from symptom onset to diagnosis

Challenge

  • Uterine fibroids (UF) affect up to 70% of women by age 50, with 20-50% experiencing clinical symptoms impacting daily life; the most common symptoms include pain and heavy menstrual bleeding (HMB)
  • Limited evidence exists on the patient-perceived disease burden of UF from prospective, observational studies
  • Myovant had two main objectives:
  • Describe the demographic and clinical characteristics of women living with HMB and moderate-to-severe pain associated with UF in clinical practice
  • Assess the real-world utilization of therapies to treat these symptoms of UF

Approach

  • Evidation leveraged its digital health measurement and engagement platform to recruit 350 women living with UF, moderate-to-severe pain, and HMB into a 4-month prospective study to assess the burden of pain and its related treatments
  • In addition to clinical and demographic characteristics, patients completed UF-specific ePROS using the UFS-QOL-SS scale, 11-point NRS on UF-associated pain, and daily surveys on pain medication use

Results

  • Participants reported a mean UF-symptom severity of 51.2 (± 19.2) and a mean worst UF-associated pain score of 7.17 (± 1.54)
  • These findings provide evidence of the significant burden that UF imposes on women – while symptom onset occurred early in life, women experienced, on average, a 9-year gap from symptom onset to diagnosis
  • Women mainly managed their UF-associated pain with over-the-counter medications, while not receiving treatments for HMB; hence, there are significant unmet diagnostic as well as treatment needs in UF

Related Therapeutic Areas: